Role of redox reactions in the vascular phenotype of hyperhomocysteinemic animals

Antioxidants and Redox Signaling

Volumn 9, Issue 11, 2007, Pages 1899-1909

  Dayal, Sanjana ^a   Lentz, Steven R ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

AMINO ACID METABOLISM; ATHEROSCLEROSIS; BLOOD VESSEL FUNCTION; CARDIOVASCULAR DISEASE; ENDOTHELIUM; HYPERHOMOCYSTEINEMIA; NONHUMAN; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; THROMBOSIS; VASCULAR ENDOTHELIUM; VASOMOTOR DISORDER;

ANIMALS; CARDIOVASCULAR DISEASES; CORONARY THROMBOSIS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FORECASTING; HYPERHOMOCYSTEINEMIA; MODELS, BIOLOGICAL; OXIDATION-REDUCTION; PHENOTYPE; RISK FACTORS; STROKE;

ANIMALIA;

EID: 35448965209     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.1806     Document Type: Review

References (106)

1. Adachi H, Hirai Y, Fujiura Y, Matsuoka H, Satoh A, and Imaizumi T. Plasma homocysteine levels and atherosclerosis in Japan: epidemiological study by use of carotid ultrasonography. Stroke 33: 2177-2181, 2002.
2. Arthur JR. The glutathione peroxidases. Cell Mol Life Sci 57: 1825-1835, 2000.
3. Bagi Z, Ungvari Z, and Koller A. Xanthine oxidase-derived reactive oxygen species convert flow-induced arteriolar dilation to constriction in hyperhomocysteinemia: possible role of peroxynitrite. Arterioscler Thromb Vas Biol 22: 28-33, 2002.
4. Bardell AL and MacLeod KM. Evidence for inducible nitric-oxide synthase expression and activity in vascular smooth muscle of streptozotocin-diabetic rats. J Pharmacol Exp Ther 296: 252-259, 2001.
5. Baumbach GL, Didion SP, and Faraci FM. Hypertrophy of cerebral arterioles in mice deficient in expression of the gene for CuZn superoxide dismutase. Stroke 37: 1850-1855, 2006.
6. Baumbach GL, Sigmund CD, Bottiglieri T, and Lentz SR. Structure of cerebral arterioles in cystathionine beta-synthase-deficient mice. Circ Res 91: 931-937, 2002.
7. Baumbach GL, Sigmund CD, and Faraci FM. Structure of cerebral arterioles in mice deficient in expression of the gene for endothelial nitric oxide synthase. Circ Res 95: 822-829, 2004.
8. Becker JS, Adler A, Schneeberger A, Huang H, Wang Z, Walsh E, Koller A, and Hintze TH. Hyperhomocysteinemia, a cardiac metabolic disease: role of nitric oxide and the p22phox subunit of NADPH oxidase. Circulation 111: 2112-2118, 2005.
9. Behr-Roussel D, Rupin A, Simonet S, Bonhomme E, Coumailleau S, Cordi A, Serkiz B, Fabiani JN, and Verbeuren TJ. Effect of chronic treatment with the inducible nitric oxide synthase inhibitor N-iminoethyl-L-lysine or with L-arginine on progression of coronary and aortic atherosclerosis in hypercholesterolemic rabbits. Circulation 102: 1033-1038, 2000.
10. Cai H and Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87: 840-844, 2000.
11. Channon KM. Tetrahydrobiopterin: regulator of endothelial nitric oxide synthase in vascular disease. Trends Cardiovasc Med 14: 323-327, 2004.
12. Chen C, Surowiec SM, Morsy AH, and Ma M. Intraperitoneal infusion of homocysteine increases intimal hyperplasia in balloon-injured rat carotid arteries. Atherosclerosis 160: 103-114, 2002.
13. Chen Z, Karaplis AC, Ackerman SL, Pogribny IP, Melnyk S, Lussier-Cacan S, Chen MF, Pai A, John SW, Smith RS, Bottiglieri T, Bagley P, Selhub J, Rudnicki MA, James SJ, and Rozen R. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 10: 433-443, 2001.
14. Clarke R. Homocysteine-lowering trials for prevention of heart disease and stroke. Semin Vasc Med 5: 215-222, 2005.
15. Cook JW, Malinow MR, Moneta GL, Taylor LM, and Orloff SL. Neointimal hyperplasia in balloon-injured rat carotid arteries: the influence of hyperhomocysteinemia. J Vasc Surg 35: 158-165, 2002.
16. Dayal S, Arning E, Bottiglieri T, Boger RH, Sigmund CD, Faraci FM, and Lentz SR. Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. Stroke 35: 1957-1962, 2004.
17. Dayal S, Bottiglieri T, Arning E, Maeda N, Malinow MR, Sigmund CD, Heistad DD, Faraci FM, and Lentz SR. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice. Circ Res 88: 1203-1209, 2001.
18. Dayal S, Brown KL, Weydert CJ, Oberley LW, Arning E, Bottiglieri T, Faraci FM, and Lentz SR. Deficiency of glutathione peroxidase-1 sensitizes hyperhomocysteinemic mice to endothelial dysfunction. Arterioscle Thromb Vasc Biol 22: 1996-2002, 2002.
19. Dayal S, Devlin AM, McCaw RB, Liu ML, Arning E, Bottiglieri T, Shane B, Faraci FM, and Lentz SR. Cerebral vascular dysfunction in methionine synthase-deficient mice. Circulation 112: 737-744, 2005.
20. Dayal S, Wilson KM, Leo L, Arning E, Bottiglieri T, and Lentz SR. Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia. Blood 108: 2237-2243, 2006.
21. De Keulenaer GW, Alexander RW, Ushio-Fukai M, Ishizaka N, and Griendling KK. Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem J 329: 653-657, 1998.
22. De Vriese AS, Blom HJ, Heil SG, Mortier S, Kluijtmans LA, Van de Voorde J, and Lameire NH. Endothelium-derived hyperpolarizing factor-mediated renal vasodilatory response is impaired during acute and chronic hyperhomocysteinemia. Circulation 109: 2331-2336, 2004.
23. Detmers PA, Hernandez M, Mudgett J, Hassing H, Burton C, Mundt S, Chun S, Fletcher D, Card DJ, Lisnock J, Weikel R, Bergstrom JD, Shevell DE, Hermanowski-Vosatka A, Sparrow CP, Chao YS, Rader DJ, Wright SD, and Pure E. Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J Immunol 165: 3430-3435, 2000.
24. Devlin AM, Arning E, Bottiglieri T, Faraci FM, Rozen R, and Lentz SR. Effect of Mthfr genotype on diet-induced hyperhomocysteinemia and vascular function in mice. Blood 103: 2624-2629, 2004.
25. Devlin AM, Bottiglieri T, Domann FE, and Lentz SR. Tissue-specific changes in H19 methylation and expression in mice with hyperhomocysteinemia. J Biol Chem 280: 25506-25511, 2005.
26. Dhillon B, Badiwala MV, Maitland A, Rao V, Li SH, and Verma S. Tetrahydrobiopterin attenuates homocysteine induced endothelial dysfunction. Mol Cell Biochem 247: 223-227, 2003.
27. Doshi SN, McDowell IF, Moat SJ, Payne N, Durrant HJ, Lewis MJ, and Goodfellow J. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 105: 22-26, 2002.
28. Ebbesen LS, Christiansen K, and Ingerslev J. Hyperhomocysteinemia due to folate deficiency is thrombogenic in rats. J Nutr 133: 2250-2255, 2003.
29. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, Heydrick S, Stark R, Klings ES, Moldovan NI, Yaghoubi M, Goldschmidt-Clermont PJ, Farber HW, Cohen R, and Loscalzo J. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 106: 483-491, 2000.
30. Feletou M and Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol 291: H985-H1002, 2006.
31. Fowler B. Homocysteine: overview of biochemistry, molecular biology, and role in disease processes. Semin Vasc Med 5: 77-86, 2005.
32. Frey RS, Rahman A, Kefer JC, Minshall RD, and Malik AB. PKCzeta regulates TNF-alpha-induced activation of NADPH oxidase in endothelial cells. Circ Res 90: 1012-1019, 2002.
33. Glaser CB, Morser J, Clarke JH, Blasko E, McLean K, Kuhn I, Chang RJ, Lin JH, Vilander L, Andrews WH, and Light DR. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity: a potential rapid mechanism for modulation of coagulation. J Clin Invest 90: 2565-2573, 1992.
34. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Iinvest 91: 2873-2879, 1993.
35. Handy DE, Zhang Y, and Loscalzo J. Homocysteine down-regulates cellular glutathione peroxidase (GPx1) by decreasing translation. J Biol Chem 280: 15518-15525, 2005.
36. Harker LA, Ross R, Slichter SJ, and Scott CR. Homocystine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 58: 731-741, 1976.
37. Harker LA, Slichter SJ, Scott CR, and Ross R. Homocystinemia: vascular injury and arterial thrombosis. N Engl J Med 291: 537-543, 1974.
38. Heinecke JW, Rosen H, Suzuki LA, and Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 262: 10098-10103, 1987.
39. Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, Ferran LJ Jr, Kohl B, Rao V, Kisiel W, Stern DM, and Schmidt AM. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 107: 675-683, 2001.
40. Hollenberg SM, Broussard M, Osman J, and Parrillo JE. Increased microvascular reactivity and improved mortality in septic mice lacking inducible nitric oxide synthase. Circ Res 86: 774-778, 2000.
41. Iafrati MD, Vitseva O, Tanriverdi K, Blair P, Rex S, Chakrabarti S, Varghese S, and Freedman JE. Compensatory mechanisms influence hemostasis in setting of eNOS deficiency. Am J Physiol 288: H1627-H1632, 2005.
42. Jacobsen DW, Catanescu O, Dibello PM, and Barbato JC. Molecular targeting by homocysteine: a mechanism for vascular pathogenesis. Clin Chem Lab Med 43: 1076-1083, 2005.
43. Jiang X, Yang F, Tan H, Liao D, Bryan RM Jr, Randhawa JK, Rumbaut RE, Durante W, Schafer AI, Yang X, and Wang H. Hyperhomocysteinemia impairs endothelial function and eNOS activity via PKC activation. Arterioscler Thromb Vasc Biol 25: 2515-2521, 2005.
44. Lang D, Kredan MB, Moat SJ, Hussain SA, Powell CA, Bellamy MF, Powers HJ, and Lewis MJ. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: role for superoxide anions. Arterioscler Thromb Vasc Biol 20: 422-427, 2000.
45. Lassegue B and Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol 285: R277-R297, 2003.
46. Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 3: 1646-1654, 2005.
47. Lentz SR, Erger RA, Dayal S, Maeda N, Malinow MR, Heistad DD, and Faraci FM. Folate dependence of hyperhomocysteinemia and vascular dysfunction in cystathionine beta-synthase-deficient mice. Am J Physiol 279: H970-H975, 2000.
48. Lentz SR and Haynes WG. Homocysteine: is it a clinically important cardiovascular risk factor? Clev Clin J Med 71: 729-734, 2004.
49. Lentz SR, Malinow MR, Piegors DJ, Bhopatkar-Teredesai M, Faraci FM, and Heistad DD. Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys. Arterioscler Thromb Vasc Biol 17: 2930-2934, 1997.
50. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, and Heistad DD. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 98: 24-29, 1996.
51. Lominadze D, Roberts AM, Tyagi N, Moshal KS, and Tyagi SC. Homocysteine causes cerebrovascular leakage in mice. Am J Physiol 290: H1206-H1213, 2006.
52. Madamanchi NR, Vendrov A, and Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 25: 29-38, 2005.
53. Marcucci R, Zanazzi M, Bertoni E, Rosati A, Fedi S, Lenti M, Prisco D, Castellani S, Abbate R, and Salvadori M. Homocysteine-lowering therapy and carotid intima-media thickness in renal transplant recipients. Transplant Proc 37: 2491-2492, 2005.
54. Matthias D, Becker CH, Riezler R, and Kindling PH. Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine. Atherosclerosis 122: 201-216, 1996.
55. Morita H, Kurihara H, Yoshida S, Saito Y, Shindo T, Oh-Hashi Y, Kurihara Y, Yazaki Y, and Nagai R. Diet-induced hyperhomocysteinemia exacerbates neointima formation in rat carotid arteries after balloon injury. Circulation 103: 133-139, 2001.
56. Mudd SH, Finkelstein JD, Refsum H, Ueland PM, Malinow MR, Lentz SR, Jacobsen DW, Brattstrom L, Wilcken B, Wilcken DE, Blom HJ, Stabler SP, Allen RH, Selhub J, and Rosenberg IH. Homocysteine and its disulfide derivatives: a suggested consensus terminology. Arterioscler Thromb Vasc Biol 20: 1704-1706, 2000.
57. Mueller CF, Laude K, McNally JS, and Harrison DG. ATVB in focus: redox mechanisms in blood vessels. Arterioscler Thromb Vasc Biol 25: 274-278, 2005.
58. Mullick AE, Zaid UB, Athanassious CN, Lentz SR, Rutledge JC, and Symons JD. Hyperhomocysteinemia increases arterial permeability and stiffness in mice. Am J Physiol 291: R1349-R1354, 2006.
59. Murthy SN, Obregon DF, Chattergoon NN, Fonseca NA, Mondal D, Dunne JB, Diez JG, Jeter JR Jr, Kadowitz PJ, Agrawal KC, McNamara DB, and Fonseca VA. Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation, and intimal hyperplasia in Sprague-Dawley rats fed a high methionine diet. Metabolism 54: 645-652, 2005.
60. Ovechkin AV, Tyagi N, Sen U, Lominadze D, Steed MM, Moshal KS, and Tyagi SC. 3-Deazaadenosine mitigates arterial remodeling and hypertension in hyperhomocysteinemic mice. Am J Physiol Lung Cell Mol Physiol 291: L905-L911, 2006.
61. Ozuyaman B, Godecke A, Kusters S, Kirchhoff E, Scharf RE, and Schrader J. Endothelial nitric oxide synthase plays a minor role in inhibition of arterial thrombus formation. Thromb Haemost 93: 1161-1167, 2005.
62. Parthasarathy S. Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochim Biophys Acta 917: 337-340, 1987.
63. Perla-Kajan J, Twardowski T, and Jakubowski H. Mechanisms of homocysteine toxicity in humans. Amino Acids 32: 561-572, 2007.
64. Robert K, Nehme J, Bourdon E, Pivert G, Friguet B, Delcayre C, Delabar JM, and Janel N. Cystathionine beta synthase deficiency promotes oxidative stress, fibrosis, and steatosis in mice liver. Gastroenterology 128: 1405-1415, 2005.
65. Rolland PH, Friggi A, Barlatier A, Piquet P, Latrille V, Faye MM, Guillou J, Charpiot P, Bodard H, Ghiringhelli O, and et al. Hyperhomocysteinemia- induced vascular damage in the minipig: captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 91: 1161-1174, 1995.
66. Sauls DL, Arnold EK, Bell CW, Allen JC, and Hoffman M. Prothrombotic and pro-oxidant effects of diet-induced hyperhomocysteinemia. Thromb Res 120: 117-126, 2007.
67. Sauls DL, Lockhart E, Warren ME, Lenkowski A, Wilhelm SE, and Hoffman M. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. Biochemistry 45: 2480-2487, 2006.
68. Sauls DL, Wolberg AS, and Hoffman M. Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. J Thromb Haemost 1: 300-306, 2003.
69. Schwahn BC, Wendel U, Lussier-Cacan S, Mar MH, Zeisel SH, Leclerc D, Castro C, Garrow TA, and Rozen R. Effects of betaine in a murine model of mild cystathionine-beta-synthase deficiency. Metabolism 53: 594-599, 2004.
70. Shukla N, Koupparis A, Jones RA, Angelini GD, Persad R, and Jeremy JY. Penicillamine administration reverses the inhibitory effect of hyperhomocysteinaemia on endothelium-dependent relaxation and superoxide formation in the aorta of the rabbit. Eur J Pharmacol 531: 201-208, 2006.
71. Spence JD. Homocysteine: call off the funeral. Stroke 37: 282-283, 2006.
72. Starkebaum G and Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 77: 1370-1376, 1986.
73. Suematsu N, Ojaimi C, Kinugawa S, Wang Z, Xu X, Koller A, Recchia FA, and Hintze TH. Hyperhomocysteinemia alters cardiac substrate metabolism by impairing nitric oxide bioavailability through oxidative stress. Circulation 115: 255-262, 2007.
74. Swanson DA, Liu ML, Baker PJ, Garrett L, Stitzel M, Wu J, Harris M, Banerjee R, Shane B, and Brody LC. Targeted disruption of the methionine synthase gene in mice. Mol Cel Biol 21: 1058-1065, 2001.
75. Symons JD, Mullick AE, Ensunsa JL, Ma AA, and Rutledge JC. Hyperhomocysteinemia evoked by folate depletion: effects on coronary and carotid arterial function. Arterioscler Thromb Vasc Biol 22: 772-780, 2002.
76. Symons JD, Rutledge JC, Simonsen U, and Pattathu RA. Vascular dysfunction produced by hyperhomocysteinemia is more severe in the presence of low folate. Am J Physiol 290: H181-H191, 2006.
77. Symons JD, Zaid UB, Athanassious CN, Mullick AE, Lentz SR, and Rutledge JC. Influence of folate on arterial permeability and stiffness in the absence or presence of hyperhomocysteinemia. Arterioscler Thromb Vas Biol 26: 814-818, 2006.
78. Tan H, Jiang X, Yang F, Li Z, Liao D, Trial J, Magera MJ, Durante W, Yang X, and Wang H. Hyperhomocysteinemia inhibits post-injury reendothelialization in mice. Cardiovasc Res 69: 253-262, 2006.
79. Tasatargil A, Dalaklioglu S, and Sadan G. Poly(ADP-ribose) polymerase inhibition prevents homocysteine-induced endothelial dysfunction in the isolated rat aorta. Pharmacology 72: 99-105, 2004.
80. Tasatargil A, Sadan G, and Karasu E. Homocysteine-induced changes in vascular reactivity of guinea-pig pulmonary arteries: role of the oxidative stress and poly (ADP-ribose) polymerase activation. Pulm Pharmacol Ther 20: 265-272, 2007.
81. Toborek M, Kopieczna-Grzebieniak E, Drozdz M, and Wieczorek M. Increased lipid peroxidation as a mechanism of methionine-induced atherosclerosis in rabbits. Atherosclerosis 115: 217-224, 1995.
82. Topal G, Brunet A, Millanvoye E, Boucher JL, Rendu F, Devynck MA, and David-Dufilho M. Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin. Free Radic Biol Med 36: 1532-1541, 2004.
83. Troen AM, Lutgens E, Smith DE, Rosenberg IH, and Selhub J. The atherogenic effect of excess methionine intake. Proc Natl Acad Sci U S A 100: 15089-15094, 2003.
84. Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, and Tyagi SC. Mechanisms of homocysteine-induced oxidative stress. Am J Physiol 289: H2649-H2656, 2005.
85. Undas A, Williams EB, Butenas S, Orfeo T, and Mann KG. Homocysteine inhibits inactivation of factor Va by activated protein C. J Biol Chem 276: 4389-4397, 2001.
86. Ungvari Z, Csiszar A, Bagi Z, and Koller A. Impaired nitric oxide-mediated flow-induced coronary dilation in hyperhomocysteinemia: morphological and functional evidence for increased peroxynitrite formation. Am J Pathol 161: 145-153, 2002.
87. Ungvari Z, Csiszar A, Edwards JG, Kaminski PM, Wolin MS, Kaley G, and Koller A. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 23: 418-424, 2003.
88. Ungvari Z, Pacher P, Rischak K, Szollar L, and Koller A. Dysfunction of nitric oxide mediation in isolated rat arterioles with methionine diet-induced hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 19: 1899-1904, 1999.
89. Upchurch GR Jr, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF Jr, and Loscalzo J. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 272: 17012-17017, 1997.
90. Verhaar MC, Stroes E, and Rabelink TJ. Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol 22: 6-13, 2002.
91. Vitvitsky V, Dayal S, Stabler S, Zhou Y, Wang H, Lentz SR, and Banerjee R. Perturbations in homocysteine-linked redox homeostasis in a murine model for hyperhomocysteinemia. Am J Physiol 287: R39-R46, 2004.
92. Wang H, Jiang X, Yang F, Gaubatz JW, Ma L, Magera MJ, Yang X, Berger PB, Durante W, Pownall HJ, and Schafer AI. Hyperhomocysteinemia accelerates atherosclerosis in cystathionine beta-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation. Blood 101: 3901-3907, 2003.
93. Wang L, Jhee KH, Hua X, DiBello PM, Jacobsen DW, and Kruger WD. Modulation of cystathionine beta-synthase level regulates total serum homocysteine in mice. Cir Res 94: 1318-1324, 2004.
94. Watanabe M, Osada J, Aratani Y, Kluckman K, Reddick R, Malinow MR, and Maeda N. Mice deficient in cystathionine betasynthase: animal models for mild and severe homocyst(e)inemia. Proc Natl Acad Sci U S A 92: 1585-1589, 1995.
95. Weiler H and Isermann BH. Thrombomodulin. J Thromb Haemost 1: 1515-1524, 2003.
96. Weiss N, Heydrick S, Zhang YY, Bierl C, Cap A, and Loscalzo J. Cellular redox state and endothelial dysfunction in mildly hyperhomocysteinemic cystathionine beta-synthase-deficient mice. Arterioscler Thromb Vasc Biol 22: 34-41, 2002.
97. Weiss N, Zhang YY, Heydrick S, Bierl C, and Loscalzo J. Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial dysfunction. Proc Natl Acad Sci U S A 98: 12503-12508, 2001.
98. Welch GN, Upchurch GR Jr, Farivar RS, Pigazzi A, Vu K, Brecher P, Keaney JF Jr, and Loscalzo J. Homocysteine-induced nitric oxide production in vascular smooth-muscle cells by NF-kappa B-dependent transcriptional activation of Nos2. Proc Assoc Am Physicians 110: 22-31, 1998.
99. Wilson KM, McCaw RB, Leo L, Arning E, Lhotak S, Bottiglieri T, Austin RC, and Lentz SR. Prothrombotic effects of hyperhomocysteinemia and hypercholesterolemia in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 27: 233-240, 2007.
100. Zhang F, Siow YL, and O K. Hyperhomocysteinemia activates NF-kappaB and inducible nitric oxide synthase in the kidney. Kidney Int 65: 1327-1338, 2004.
101. Zhang X, Li H, Jin H, Ebin Z, Brodsky S, and Goligorsky MS. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol 279: F671-F678, 2000.
102. Zhou J, Lhotak S, Hilditch BA, and Austin RC. Activation of the unfolded protein response occurs at all stages of atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation 111: 1814-1821, 2005.
103. Zhou J, Moller J, Danielsen CC, Bentzon J, Ravn HB, Austin RC, and Falk E. Dietary supplementation with methionine and homocysteine promotes early atherosclerosis but not plaque rupture in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 21: 1470-1476, 2001.
104. Zhou J, Moller J, Ritskes-Hoitinga M, Larsen ML, Austin RC, and Falk E. Effects of vitamin supplementation and hyperhomocysteinemia on atherosclerosis in apoE-deficient mice. Atherosclerosis 168: 255-262, 2003.
105. Zhou J, Werstuck GH, Lhotak S, de Koning AB, Sood SK, Hossain GS, Moller J, Ritskes-Hoitinga M, Falk E, Dayal S, Lentz SR, and Austin RC. Association of multiple cellular stress pathways with accelerated atherosclerosis in hyperhomocysteinemic apolipoprotein E-deficient mice. Circulation 110: 207-213, 2004.
106. Zou MH, Shi C, and Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 109: 817-826, 2002.